Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04200365 · ClinicalTrials.gov registry record · Phase 2
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
A Phase 2 study, sponsored by SCRI Development Innovations.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04200365 is a Phase 2 study that was terminated before completion, run by SCRI Development Innovations. The registered enrollment target is 15 participants.
The verdict
NCT04200365, a Phase 2 study, was terminated before completion, sponsored by SCRI Development Innovations.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study is being done in patients who have been receiving corticosteroids or other immunosuppressive therapies for the treatment of cGVHD for at least 6 months. The purpose of this study is to find out if itacitinib in combination with corticosteroids or other immunosuppressive therapies is safe and effective in people with cGVHD.
Interventions
- DRUG Itacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-06-05 |
| Est. Completion | 2023-09-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04200365
The ClinicalTrials.gov registry entry for NCT04200365 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Itacitinib is the first listed.
NCT04200365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04200365 about?
NCT04200365 is a clinical study titled "A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)". This study is being done in patients who have been receiving corticosteroids or other immunosuppressive therapies for the treatment of cGVHD for at least 6 months. The purpose of this study is to find out if itacitinib in combination with corticosteroids or other immunosuppressive therapies is safe ...
What is the current status of trial NCT04200365?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-06-05. Estimated completion is 2023-09-07.
What interventions are being tested in trial NCT04200365?
The interventions under investigation include: Itacitinib (DRUG).
Who is sponsoring clinical trial NCT04200365?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.